Effect Of GW501516X On How The Heart Obtains And Uses Energy

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00318617
First received: April 25, 2006
Last updated: March 15, 2012
Last verified: February 2011

April 25, 2006
March 15, 2012
December 2005
Not Provided
Energy-related chemicals and heart contraction, determined by MRI measurement of the heart.
Same as current
Complete list of historical versions of study NCT00318617 on ClinicalTrials.gov Archive Site
Additional energy-related chemicals, determined by MRI measurement of the heart. Blood proteins. Safety of GW501516X.
Same as current
Not Provided
Not Provided
 
Effect Of GW501516X On How The Heart Obtains And Uses Energy
A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects

The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.

Not Provided
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Dyslipidaemias
  • Heart Failure
Drug: GW510516X
Other Name: GW510516X
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
30
Not Provided
Not Provided

Inclusion criteria:

  • Non-smoking.
  • Body Mass Index of greater than 27 and less than 32 and who weigh 120 kg (264 lbs) or less and have a waist circumference of greater than 95 cm (37.5 inches).

Exclusion criteria:

  • History of muscle disease, coagulation disorders, heart disease or abnormal heart rhythm (or a family history of early coronary artery disease).
  • Documented diabetes, hypoglycemia, thyroid disfunction or adrenal disorder.
Male
18 Years to 40 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00318617
PAD100964
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP